Влияние полиморфизма генов CYP2C9 и VKORC1 на безопасность терапии варфарином

Влияние полиморфизма генов CYP2C9 и VKORC1 на безопасность терапии варфарином

Автор: Зотова И.В., Никитин А.Г., Фаттахова Э.Н., Бровкин А.Н., Ходырев Д.С., Лаврикова Е.Ю., Исаева М.Ю., Косухина А.С., Носиков В.В., Затейщиков Д.А.

Журнал: Клиническая практика @clinpractice

Рубрика: Оригинальные исследования

Статья в выпуске: 4 (16), 2013 года.

Бесплатный доступ

Для изучения распределения аллелей и генотипов полиморфных маркеров генов CYP2C9 и VKORC1 у русских больных, проживающих в г. Москве, и оценки влияния генетических факторов на терапию варфарином было проведено генотипирование 400 пациентов. Дозировка варфарина, необходимая для достижения целевых значений МНО, различалась у носителей различных генотипов полиморфных маркеров гена CYP2C9, при этом наибольшая средняя доза требовалась для носителей генотипа *1/*1, а наименьшая – для носителей аллелей *2 и *3. Для полиморфного маркера G(-1639)A гена VKORC1 дозировка варфарина, необходимая для достижения целевых значений МНО, различалась у носителей различных генотипов, наибольшая средняя доза требовалась носителям генотипа GG, а наименьшая – носителям генотипа AA. Полученные данные позволят разработать более точный алгоритм выбора начальной дозы варфарина в зависимости от генотипов полиморфных маркеров генов CYP2C9 и VKORC1.

Еще

Варфарин, полиморфный маркер, индивидуальная чувствительность, фармакогенетика

Короткий адрес: https://sciup.org/14338471

IDR: 14338471

Список литературы Влияние полиморфизма генов CYP2C9 и VKORC1 на безопасность терапии варфарином

  • Prendergast F G, Mann K G. Differentiation of metal ion-induced transitions of prothrombin fragment J. Biol. Chem. 1977; 252 (3): 840-50.
  • Borowski M, Furie B C, Bauminger S, Furie B. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. Conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. J. Biol. Chem. 1986; 261 (32): 14969-75.
  • Nelsestuen G L. Role of gamma-carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. J. Biol. Chem. 1976; 251 (18): 5648-56.
  • Nelsestuen G L, Zytkovicz T H, Howard J B. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J. Biol. Chem. 1974; 249 (19): 6347-50.
  • Choonara I A, Malia R G, Haynes B P et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol. 1988; 25 (1): 1-7.
  • Owen Ryan P., Gong Li, Sagreiya Hersh, Klein Teri E., Altman Russ B. VKORC1 Pharmaco-genomics Summary. Pharmacogenet Genomics. 2010; 20 (10): 642-44.
  • Wadelius M, Pirmohamed M. Pharmaco-genetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007; 7 (2): 99-111.
  • Schwarz U I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003; 33 Suppl 2: 23-30.
  • Tai Guoying, Farin Frederico, Rieder Mark J et al. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics. 2005; 15 (7): 475-81.
  • Muszkat Mordechai, Blotnik Simcha, Elami Amir, Krasilnikov Irena, Caraco Yoseph. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther. 2007; 29 (3): 427-37.
  • Higashi Mitchell K, Veenstra David L, Kondo L Midori et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287 (13): 1690-98.
  • Li Tao, Chang Chun-Yun, Jin Da-Yun et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004; 427 (6974): 541-44.
  • Rost Simone, Fregin Andreas, Ivaskevicius Vytautas et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427 (6974), 537-41.
  • Obayashi Kyoko, Nakamura Katsunori, Kawana Junichi et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006; 80 (2): 169-78.
  • Loebstein Ronen, Dvoskin Ilana, Halkin Hillel et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109 (6): 2477-80.
  • D'Andrea Giovanna, D'Ambrosio Rosa Lucia, Di Perna Pasquale et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005; 105 (2): 645-49.
  • Rieder Mark J, Reiner Alexander P, Gage Brian F et al. Effect of VKORC1 haplotypes on transcriptional. regulation and warfarin dose. N Engl J Med. 2005; 352 (22): 2285-93.
  • Harrington Dominic J, Underwood Sarah, Morse Colin et al. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost. 2005; 93 (1): 23-26.
  • Bodin L, Horellou M H, Flaujac C, Loriot M A, Samama M M. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost. 2005;3 (7): 1533-35.
  • Yuan Hsiang-Yu, Chen Jin-Jer, Lee M T Michael et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14 (13): 1745-51.
  • Geisen Christof, Watzka Matthias, Sittinger Katja et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005; 94 (4): 773-9.
  • Aquilante Christina L., Langaee Taimour Y., Lopez Larry M. et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006; 79 (4): 291-302.
  • Takahashi Harumi, Wilkinson Grant R, Nutescu Edith A et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006; 16 (2): 101-110.
  • Hynicka Lauren M, Cahoon William D Jr, Bukaveckas Bonny L. Genetic testing for warfarin therapy initiation. Ann Pharmacother. 2008; 42 (9): 1298-1303.
  • Johns M B, Paulus-Thomas J E. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. Anal Biochem. 1989;180 (2): 276-8.
  • Калькулятор для расчета статистики в исследованиях «случай-контроль» [http://gen-exp.ru/calculator_or.php].
  • Lindh Jonatan D, Lundgren Stefan, Holm Lennart, Alfredsson Lars, Rane Anders. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther. 2005; 78 (5): 540-50.
  • Peyvandi Flora, Spreafico Marta, Siboni Simona Maria, Moia Marco, Mannucci Pier Mannuccio. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther. 2004; 75 (3): 198-203.
  • Joffe Hylton V, Xu Ruliang, Johnson F Bradley et al. Warfarin dosing and cytochrome P450 2C9 poly-morphisms. Thromb Haemost. 2004; 91(6): 1123-28.
  • Leung A Y, Chow H C, Kwong Y L et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood. 2001;98 (8): 2584-87.
  • Tabrizi Arash Rafii, Zehnbauer Barbara A, Borecki Ingrid B et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002; 194 (3): 267-73.
  • Scordo Maria Gabriella, Pengo Vittorio, Spina Edoardo et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002; 72 (6): 702-10.
  • Visser Loes E, van Vliet Martin, van Schaik Ron H N et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics. 2004; 14 (1): 27-33.
  • Voora Deepak, Eby Charles, Linder Mark W et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005; 93 (4):700-705.
  • Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000; 96 (5): 1816-19.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp